No: AH 03052021 May 17, 2021 Subject: Management Discussion & Analysis (MD&A) for the financial statements of the 1st quarter of fiscal year 2021 ended as of March 31, 2021 To: The President The Stock
No: AH 02112021 November 12, 2021 Subject: Management Discussion & Analysis (MD&A) for the financial statements of the 3rd quarter of fiscal year 2021 ended as of September 30, 2021 To: The President
No: AH 03052022 May 17, 2022 Subject: Management Discussion & Analysis (MD&A) for the Financial Statements of the 1st Quarter of Fiscal Year 2022 Ended as of March 31, 2022 To: The President The Stock
IP_AC/001/2563 February 24, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited
, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited ( “ the Company” ) would like
Ratio), as specified in the Terms of Rights, effective from the end of the fiscal year of 2023 until the end of the fiscal year of 2025, and for allowing the issuer to enter any negotiations or
months, end of March 31, 2019 Financial Statement Consolidate financial statement % revenue from sales Q1/2019 Q1/2018 increase(decrease) Q1/2019 Q1/2018 Revenues from sales 67.47 56.46 11.01 19.50% 100.00
, end of June 30, 2020 Financial Statement Consolidate financial statement % Revenue from sales Q1/2020 Q1/2019 increase (decrease) Q1/2020 Q1/2019 Revenue from sales 85.68 121.53 (35.85) (29.50%) 100.00